These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 3030932)
1. Kala-azar in Bihar. Prasad LS Indian J Pediatr; 1987; 54(1):103-10. PubMed ID: 3030932 [No Abstract] [Full Text] [Related]
2. Chemotherapy of leishmaniasis in India. Thakur CP Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933 [No Abstract] [Full Text] [Related]
3. Treatment of kala-azar in India. Thakur CP Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871 [No Abstract] [Full Text] [Related]
4. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study. Singh S ; Kumar J; Singh R; Dwivedi SN Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183 [TBL] [Abstract][Full Text] [Related]
5. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment of kala-azar. Chandra J; Patwari AK Indian Pediatr; 1994 Jun; 31(6):741-8. PubMed ID: 7896411 [No Abstract] [Full Text] [Related]
7. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Thakur CP; Dedet JP; Narain S; Pratlong F Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558 [TBL] [Abstract][Full Text] [Related]
8. Amphotericin B in visceral leishmaniasis. Jha BB Indian Pediatr; 1996 Nov; 33(11):971. PubMed ID: 9141838 [No Abstract] [Full Text] [Related]
9. [A case of antimony resistant kala-azar cured with amphotericin B]. Chen SB; Yang CM; Zhang CJ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767 [No Abstract] [Full Text] [Related]
10. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Mishra M; Biswas UK; Jha DN; Khan AB Lancet; 1992 Nov; 340(8830):1256-7. PubMed ID: 1359322 [TBL] [Abstract][Full Text] [Related]
11. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Thakur CP; Narayan S; Ranjan A Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554 [TBL] [Abstract][Full Text] [Related]
12. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Thakur CP Trans R Soc Trop Med Hyg; 1984; 78(3):391-8. PubMed ID: 6087515 [TBL] [Abstract][Full Text] [Related]
13. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India. Thakur CP; Ahmed S Indian J Med Res; 2001 Jan; 113():14-8. PubMed ID: 11280166 [TBL] [Abstract][Full Text] [Related]
14. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
15. Recent advances in the treatment of visceral leishmaniasis. Davidson RN; Croft SL Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221 [No Abstract] [Full Text] [Related]
16. [Treatment of visceral leishmaniasis or kala-azar (author's transl)]. Laroche R; Sirol J; Poli L Med Trop (Mars); 1978; 38(4):401-4. PubMed ID: 215868 [No Abstract] [Full Text] [Related]
17. Challenges in the management of visceral leishmaniasis. Sundar S; Kumar A Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268 [No Abstract] [Full Text] [Related]
18. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Thakur CP; Narain S; Kumar N; Hassan SM; Jha DK; Kumar A Ann Trop Med Parasitol; 1997 Sep; 91(6):611-6. PubMed ID: 9425363 [TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665 [TBL] [Abstract][Full Text] [Related]
20. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]